VENUSREM

Venus Remedies Share Price

₹340.05 +2.45 (0.73%)

20 May, 2025 12:03

SIP TrendupStart SIP in VENUSREM

Start SIP

Performance

  • Low
  • ₹336
  • High
  • ₹345
  • 52 Week Low
  • ₹270
  • 52 Week High
  • ₹428
  • Open Price₹343
  • Previous Close₹338
  • Volume17,699

Investment Returns

  • Over 1 Month + 0.43%
  • Over 3 Month + 10.12%
  • Over 6 Month + 15.78%
  • Over 1 Year + 11.49%
SIP Lightning

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 455
  • P/B Ratio
  • 0.9
  • Average True Range
  • 13.73
  • EPS
  • 20.85
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.01
  • RSI
  • 62.92
  • MFI
  • 71.05

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹340.05
+ 2.45 (0.73%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹316.96
  • 50 Day
  • ₹311.99
  • 100 Day
  • ₹312.42
  • 200 Day
  • ₹317.46

Resistance and Support

341.3 Pivot Speed
  • R3 360.00
  • R2 355.00
  • R1 346.30
  • S1 332.60
  • S2 327.60
  • S3 318.90

What's your outlook on Venus Remedies?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 648.08 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 7% is okay, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 5% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-04 Quarterly Results
2024-10-29 Quarterly Results
2024-08-13 Quarterly Results & A.G.M.
2024-05-30 Audited Results
2024-02-14 Quarterly Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
1.11%
45.42%
11.71%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹340 As on 20 May, 2025 | 11:49

The Market Cap of Venus Remedies is ₹454.5 Cr As on 20 May, 2025 | 11:49

The P/E ratio of Venus Remedies is 13 As on 20 May, 2025 | 11:49

The PB ratio of Venus Remedies is 0.9 As on 20 May, 2025 | 11:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23